Sale!

Keytruda

$1,700.00

Keytruda (pembrolizumab) is a medicine utilized for the treatment of cutting edge melanoma, metastatic nonsquamous NSCLC, intermittent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), repetitive traditional Hodgkin Lymphoma (cHL), privately progressed or metastatic urothelial carcinoma, strong growths having the biomarkers MSI-H or dMMR, intermittent privately progressed or metastatic gastric or gastroesophageal intersection adenocarcinoma.

Oncology :Urothelial Carcinoma, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Skin Cancer

Method of Action Monoclonal counter acting agent (immunotherapy)

Administration Intravenous

Administrative office approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia

Oncology Urothelial Carcinoma, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Skin Cancer

Method of Action Monoclonal counter acting agent (immunotherapy)

Administration Intravenous

Administrative office approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia

 

What is Keytruda (pembrolizumab) for? | Buy Keytruda for Lung Cancer

Keytruda (pembrolizumab) is a monoclonal counter acting agent (immunotherapy) showed for the treatment of individuals with:

progressed (unresectable or metastatic) melanoma

metastatic nonsquamous NSCLC as first-line treatment in mix with pemetrexed and carboplatin[

intermittent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

intermittent traditional Hodgkin Lymphoma (cHL)

privately progressed or metastatic urothelial carcinoma

strong growths having the biomarkers MSI-H or dMMR[1,16]

intermittent privately progressed or metastatic gastric or gastroesophageal intersection adenocarcinoma

progressed renal cell carcinoma (RCC).

locally intermittent unresectable or metastatic triple-negative bosom disease (TNBC) whose growths express PD-L1.

It is accessible as a powder for intravenous implantation (dribble) containing 100mg of pembrolizumab per vial.

Note: Keytruda (pembrolizumab) is at present just accessible in 100mg structure (100mg/4ml). There used to be a 50mg show however this has been stopped as of March fifteenth, 2019.

How does Keytruda (pembrolizumab) work?

Keytruda (pembrolizumab) is a monoclonal neutralizer, a sort of protein that has been intended to perceive and join to a particular design (called an antigen) that is found in specific cells in the body.

Keytruda (pembrolizumab) has been intended to append to and block a receptor called ‘modified cell passing 1’ (PD-1), which switches off the action of specific cells of the safe framework (the body’s regular guards) called T cells. By impeding PD-1, pembrolizumab forestalls PD-1 from turning off these invulnerable cells, in this manner expanding the capacity of the insusceptible framework to kill canc cells

Reviews

There are no reviews yet.

Be the first to review “Keytruda”

Your email address will not be published. Required fields are marked *

Shopping Cart